Cholesterol Lowering Effect of Cardio-Complement, an Ayurveda Formulation

Cholesterol Lowering Effect of Cardio-Complement, an Ayurveda Formulation: Feasibility Study on Patients With Mild-to-moderate Hypercholesterolemia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04974853

Enrollment

Registered

2021-07-23

Start date

2021-06-01

Completion date

2021-07-05

Last updated

2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Ayurveda, Cholesterol, Cardiovascular Diseases, Hyperlipidemia

Brief summary

The aim of this feasibility study was to assess the lipid-lowering effects and safety of a Ayurveda formulation containing Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer)

Detailed description

The COVID-19 related lockdowns severely affected the healthcare in India, specially in second wave of COVID-19. This research presents the applicability of Ayurveda formulation to analyze the impact on lipid profile during the lockdown. Patients with hyperlipidemia who referred to Gyansanjeevani were recruited. All participants were enrolled in the study after a complete physical examination and medical history remotely over the virtual secure platform.

Interventions

COMBINATION_PRODUCTCardio-complement

Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Age between 18 and 65 years * BMI between 18.5 and 40 kg/m2 * Total Cholesterol \>180 mg/dl * No clinically significant medical history * Willing to participate to the study by complying with the protocol * Able to provide written informed consent

Exclusion criteria

* Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder, * Severe chronic disease * History of ischemic cardiovascular event, * Uncontrolled hypertension * Under treatment or dietary supplement which could affect study parameter

Design outcomes

Primary

Measure	Time frame
Reduction of LDL-cholesterol	Change from baseline to 2 weeks

Secondary

Measure	Time frame
Reduction of total cholesterol	Changes from baseline to 2 weeks
Increase of HDL cholesterol	Change from baseline to 2 weeks
Reduction of Triglycerides	Change from baseline to 2 weeks

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026